nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.04.2011 | Original Article

Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin

verfasst von: Katharina Effenberger-Neidnicht, Rainer Schobert

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Doxorubicin is a mainstay of cancer chemotherapy despite its clinical limitations that arise from its cardiotoxicity and the high incidence of multi-drug resistance. Recent studies revealed a protective effect of thymoquinone, a non-toxic constituent of the essential oil of Nigella sativa, against doxorubicin-induced cardiotoxicity. We now investigated the influence of thymoquinone on various other effects exerted by doxorubicin in human cancer cells.

Methods

Doxorubicin, thymoquinone and equimolar mixtures of both were tested for cytotoxicity on human cells of HL-60 leukaemia, 518A2 melanoma, HT-29 colon, KB-V1 cervix, and MCF-7 breast carcinomas as well as multi-drug-resistant variants thereof and on non-malignant human fibroblasts (HF). Apoptosis induction was analysed via DNA fragmentation, activity studies of the caspases-3, -8 and -9, determination of changes in the mitochondrial membrane potential and in the ratio of the mRNA expressions of pro- and anti-apoptotic proteins bax and bcl-2. The generation of reactive oxygen species (ROS) was assessed by the NBT assay.

Results

Thymoquinone improved the anti-cancer properties of doxorubicin in a cell line-specific manner. We found a significant rise of the growth inhibition by doxorubicin in HL-60 and multi-drug-resistant MCF-7/TOPO cells when thymoquinone had been added. The mode of action of both drugs and of their mixture was mainly apoptotic. In HL-60 cells, the drug mixture caused an additional concentration maximum of effector caspase-3 not observed for either of the pure drugs. The impact of the drug mixture on the mitochondria of HL-60 cells was also greater than those of the individual quinones alone. In addition, the drug mixture led to a higher concentration of reactive oxygen species in HL-60 cells.

Conclusions

In summary, thymoquinone is a booster for the anti-cancer effect of doxorubicin in certain cancer cell lines. Distinct improvements on efficacy, selectivity, and even breaches of multi-drug resistance were observed for equimolar mixtures of doxorubicin and thymoquinone.

Graphical abstract

Cragg GM, Grothaus PG, Newman DJ (2009) Impact of natural products on developing new anti-cancer agents. Chem Rev 109:3012–3043PubMedCrossRef

Colucci MA, Moody CJ, Couch GD (2008) Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org Biomol Chem 6:637–656PubMedCrossRef

Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135–160PubMedCrossRef

Robert J (1998) Anthracyclines. In: Grochow LB, Ames MM (eds) A clinician′s guide to chemotherapy. pharmacokinetic and pharmacodynamics, Williams & Wilkins, Baltimore, pp 93–173

Badary OA, Gamal El-Din AM (2001) Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. Cancer Detect Prev 25:362–368PubMed

Gali-Muhtasib H, Roessner A, Schneider-Stock R (2006) Thymoquinone: A promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 38:1249–1253PubMedCrossRef

Gali-Muhtasib H, Ocker M, Kuester D, Krueger S, El-Hajj Z, Diestel A, Evert M, El-Najjar N, Peters B, Jurjus A, Roessner A, Schneider-Stock R (2008) Thymoquinone reduces mouse colon tumour cell invasion and inhibits tumour growth in murine colon cancer models. J Cell Mol Med 12:330–342PubMedCrossRef

Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A, Schneider-Stock R (2004) Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via p53-dependent mechanism. Int J Oncol 25:857–866PubMed

El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA (2005) Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer 117:409–417PubMedCrossRef

10.

Breyer S, Effenberger K, Schobert R (2009) Effects of thymoquinone-fatty acid conjugates on cancer cells. Chem Med Chem 4:761–768PubMed

11.

Effenberger K, Breyer S, Schobert R (2010) Terpene conjugates of the nigella sativa seed oil constituent thymoquinone with enhanced efficacy in cancer cells. Chem Biodiv 7:129–139CrossRef

12.

Effenberger K, Breyer S, Schobert R (2010) Modulation of doxorubicin activity in cancer cells by conjugation with fatty acyl and terpenyl hydrazones. Eur J Med Chem 45:1947–1954PubMedCrossRef

13.

Al-Shabanah OA, Badary OA, Nagi MN, Al-Gharably NM, Al-Rikabi AC, Al-Bekairi AM (1998) Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exp Clin Cancer Res 17:193–198PubMed

14.

Nagi MN, Mansour MA (2000) Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res 41:283–289PubMedCrossRef

15.

Badary OA, Al-Shabanah OA, Nagi MN, Al-Rikabi AC, Elmazar MM (1999) Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur J Cancer Prev 8:435–440PubMedCrossRef

16.

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65:55–63CrossRef

17.

Earnshaw WC, Martins LM, Kaufmann SC (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68:383–424PubMedCrossRef

18.

Bas A, Forsberg G, Hammarström S, Hammarström ML (2004) Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T-lymphocytes. Scand J Immunol 59:560–573CrossRef

19.

Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedCrossRef

20.

Rook GAW, Steele J, Umar S, Dockrell HM (1985) A simple method for the solubilisation of reduced NBT, and its use as a colorimetric assay for the activation of human macrophages by gamma interferon. J Immunol Methods 82:161–167PubMedCrossRef

21.

Chou TC, Talalay P (1981) Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and non-exclusive inhibitors. Eur J Biochem 115:207–216PubMedCrossRef

22.

Chou TC, Talalay P (1984) Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzymol Regul 22:27–55CrossRef

23.

Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanarama B (2004) Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J Biol Chem 279:25535–25543PubMedCrossRef

24.

Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S (2005) Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76:1439–1453PubMedCrossRef

25.

Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 55:727–741CrossRef

26.

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in anti-tumour activity and cardiotoxicity. Pharmacol Rev 56:185–229PubMedCrossRef

27.

El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker M, Gandesiri M, Schneider-Stock R, Gala-Muhtasib H (2010) Reactive oxygen species mediated thymoquinone-induced apoptosis and activate ERK and JNK signalling. Apoptosis 15:183–195PubMedCrossRef

28.

Badary OA, Taha RA, El-Din AMG, Abdel-Wahab MH (2003) Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol 26:87–98PubMedCrossRef

29.

Benimetskaya L, Lai JC, Khvorova A, Wu S, Hua E, Miller P, Zhang LM, Stein CA (2004) Relative bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin Cancer Res 10:8371–8379PubMedCrossRef

30.

Budihardjo I, Oliver H, Lutter M, Luo X, Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:269–290PubMedCrossRef

31.

Bossy-Wetzel E, Newmeyer DD, Green DR (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independent of mitochondrial transmembrane depolarization. EMBO J 17:37–49PubMedCrossRef

Titel: Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin
verfasst von: Katharina Effenberger-Neidnicht
Rainer Schobert
Publikationsdatum: 01.04.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1386-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin

Abstract

Purpose

Methods

Results

Conclusions

Graphical abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells

A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors

Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers

Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie